As Japan approaches the Fiscal System Council’s “autumn recommendation,” a notable shift is taking shape. The Ministry of Finance (MOF),…
BUSINESS
ASKA Keeps Defense Policy in Place as Dalton Dispute Persists
ASKA Pharmaceutical Holdings said on October 10 that it will maintain the defense policy introduced in July to counter a large-scale share purchase attempt by US investment fund Dalton Investments and its allies, saying that concerns have yet to be…
To read the full story
Related Article
- Dalton Drops ASKA Stake Increase Plan, Slams Firm’s “Self-Preservation”
October 1, 2025
- ASKA Presses Dalton Again for Stake Plan Details after Public Statement
September 17, 2025
- ASKA Repeats Request to Dalton after Dismissive Email on Stake Plan
September 3, 2025
- ASKA Presses Dalton for Transparency on 30% Stake Plan
August 26, 2025
- Dalton Signals Plan to Lift ASKA Stake to 30%; Board Weighs Countermeasures
August 19, 2025
- ASKA Moves to Counter Dalton Investments’ Rapid Share Purchase
July 2, 2025
BUSINESS
- Nxera Unveils Restructuring Plan to Return to Profit, 15% Job Cuts in Japan and UK
November 18, 2025
- Vital KSK to Repurpose Shield’s Iron Deficiency Drug for PAH in Japan
November 18, 2025
- Lundbeck Files Anti-CGRP Antibody Eptinezumab in Japan
November 18, 2025
- Nipro Files for Full Approval of Stemirac Cell Therapy
November 18, 2025
- Dupixent 200 mg Pen Now Available in Japan: Sanofi
November 18, 2025
Japan is set to tighten reimbursement rules for regenerative medicine products granted conditional, time-limited approval, with Central Social Insurance Medical…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
In the complex tapestry of leadership, awareness isn’t just a desirable trait; it’s the bedrock upon which success is built. It’s the lens through which leaders perceive, interpret, and navigate the ever-shifting landscape of their organizations and industries. Without it,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…